Interaction of combinations of drugs, chemosensitisers, and peptides with the P-glycoprotein multidrug transporter

被引:32
作者
DiDiodato, G [1 ]
Sharom, FJ [1 ]
机构
[1] UNIV GUELPH,GUELPH WATERLOO CTR GRAD WORK CHEM,DEPT CHEM & BIOCHEM,GUELPH,ON N1G 2W1,CANADA
关键词
multidrug resistance; plasma membrane vesicles; drug transport; median effect analysis; synergism; antagonism;
D O I
10.1016/S0006-2952(97)00007-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
P-Glycoprotein functions as an ATP-driven efflux pump for hydrophobic natural products andeptides, and gives rise to resistance to multiple chemotherapeutic drugs. The inhibition of colchicine transport via P-glycoprotein by various compounds was determined in a plasma membrane vesicle model system. A chemotherapeutic drug (vinblastine) and several chemosensitizers (verapamil, reserpine, cyclosporin A) and hydrophobic peptides (N acetyl-leucyl-leucyl-methioninal, leupeptin, pepstatin A, valinomycin) were exam ined, both as individual species and as combinations of compounds. The median effect analysis was used to determine the concentration of each combination required to produce a median effect, D-m, as well as the sigmoidicity of the concentration-effect plot, m. The combination of cyclosporin A and verapamil was the only one established to be mutually nonexclusive, whereas several mutually exclusive pairs of compounds were identified. The combination index, CI, was calculated for several combinations of drugs, chemosensitizers, and peptides, and used to ascertain whether effects were synergistic, antagonistic, or additive. Some combinations (vinblastine/verapamil; verapamil/valinomycin) showed antagonism over the entire concentration range. Other combinations (valinomycinl/N acetyl-leucyl-leucyl-methioninal; cyclosporin A/verapamil) displayed both synergism and antagonism over different regions of the CI plot. Many combinations of compounds displayed additive interactions over most of the CI plot. The median effect analysis may be helpful in identifying potentially useful additive or synergistic combinations of compounds for reversal of Pgp-mediated drug resistance. (C) 1997 Elsevier Science Inc.
引用
收藏
页码:1789 / 1797
页数:9
相关论文
共 36 条
  • [1] Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein
    Ayesh, S
    Shao, YM
    Stein, WD
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 1996, 1316 (01): : 8 - 18
  • [2] P-glycoproteins and multidrug resistance
    Bellamy, WT
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1996, 36 : 161 - 183
  • [3] Interaction of cytostatics and chemosensitizers with the dexniguldipine binding site on P-glycoprotein
    Boer, R
    Ulrich, WR
    Haas, S
    Borchers, C
    Gekeler, V
    Boss, H
    Przybylski, M
    Schodl, A
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 295 (2-3) : 253 - 260
  • [4] Reversible labeling of a chemosensitizer binding domain of p-glycoprotein with a novel 1,4-dihydropyridine drug transport inhibitor
    Boer, R
    Dichtl, M
    Borchers, C
    Ulrich, WR
    Marecek, JF
    Prestwich, GD
    Glossmann, H
    Striessnig, J
    [J]. BIOCHEMISTRY, 1996, 35 (05) : 1387 - 1396
  • [5] Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity
    Borgnia, MJ
    Eytan, GD
    Assaraf, YG
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (06) : 3163 - 3171
  • [6] BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
  • [7] DERIVATION AND PROPERTIES OF MICHAELIS-MENTEN TYPE AND HILL TYPE EQUATIONS FOR REFERENCE LIGANDS
    CHOU, TC
    [J]. JOURNAL OF THEORETICAL BIOLOGY, 1976, 59 (02) : 253 - 276
  • [8] ANALYSIS OF COMBINED DRUG EFFECTS - A NEW LOOK AT A VERY OLD PROBLEM
    CHOU, TC
    TALALAY, P
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1983, 4 (11) : 450 - 454
  • [9] QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS
    CHOU, TC
    TALALAY, P
    [J]. ADVANCES IN ENZYME REGULATION, 1984, 22 : 27 - 55
  • [10] Doige C A, 1991, Protein Expr Purif, V2, P256, DOI 10.1016/1046-5928(91)90081-S